Cytori shares soar on Pacific Rim cell therapy pact; Biocartis raises €30M; OncoMed earns $15M milestone;

Biotech News

@FierceBiotech: ImmunoGen scuttles lead PhII armed-antibody trial after tracking infection risk. More | Follow @FierceBiotech

@JohnCFierce: Novartis chopping 371 research jobs in global R&D reorganization. Goodbye, Horsham. Article | Follow @JohnCFierce

@DamianFierce: EW's long-running misfortunes continue with a Class I recall of a bypass device. Story | Follow @DamianFierce

> San Diego-based Cytori Therapeutics ($CYTX) says it has forged a $531 million licensing deal covering its cell therapy technology. A Beijing-based company called Lorem Vascular is providing a $24 million upfront equity purchase along with an order for its Celution devices. Not much is known about Lorem Vascular and its web page is little more than the company name with a brief description of its operations. Cytori says that Lorem will pay up to $500 million in milestones for a 30-year pact covering the region. The biotech's shares soared 65% on the news. Release

> The European diagnostics company Biocartis has raised  €30 million in a Series E round. Release

> Redwood City, CA-based OncoMed ($OMED) has earned a $15 million milestone from Bayer, which launched a Phase Ia study of OMP-54F28, an antagonist of the Wnt pathway. Release

> Germany's Evotec AG has forged a research collaboration with the Leukemia & Lymphoma Society. Release

> ADC Therapeutics has licensed antibodies from Five Prime. Release

Medical Device News

@FierceMedDev: Edwards' recall gets FDA's 'deadly' label as problems pile up. Story | Follow @FierceMedDev

@MarkHFierce: CardioDx set the terms for its IPO, upping the range. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Infraredx raises more cash to back imaging system ramp-up. Story

> Medtronic, Boston Scientific unleash patent fight at Supreme Court. More

Pharma News

@FiercePharma: Monday's top special report: Top 10 Drug Patent Losses 2014. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI: J&J to pay $2.2B to wrap up longstanding Risperdal marketing probe. Story | Follow @CarlyHFierce

> Teva's ex-CEO reportedly forced polygraph tests on board to plug media leaks. More

> Novartis eyes animal health sale as first slim-down move: Bloomberg. Story

> Analyst's worst-case on Brilinta probe? Feds force AstraZeneca blood thinner off market. Article

Pharma Manufacturing News

> Merck to give pink slips to 500 West Point workers this holiday season. More

> PwC warns quality failings could slow growth of Indian biopharma. Story

> Developer pitches plan for Boston R&D and manufacturing complex. News

> Stalling biosimilars give Roche confidence to reopen Genentech plant. Report

> Novartis puts OTC unit and its troubled plant on second tier of sale priorities. Item

> FDA outlines plan to incentivize high-quality manufacturing. Article

Biotech Research News

@EmilyMFierce: Fewer NIH grants affected by sequestration than initially projected. Item | Follow @EmilyMFierce

> Survey details impact of federal cuts, sequestration on scientific research. More

> Key HIV protein structure revealed. Story

> Prana compound restores learning, memory loss in mice. Article

> Fewer NIH grants affected by sequestration than initially projected. News

> Sage molecule could treat a wide range of CNS disorders. Report

> Study: Genetics drive neurocognitive decline in aging. More

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.